Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05202613
Other study ID # 6496
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date January 4, 2022
Est. completion date December 2022

Study information

Verified date January 2022
Source University of Roma La Sapienza
Contact Gabriella d'Ettorre, Professor, MD
Phone 0649970801
Email gabriella.dettorre@uniroma1.it
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The HIV-infected population is aging due to the success of combination antiretroviral therapy, which prolongs survival, as well as the growing number of newly diagnosed cases in adults 50 years old and over. This real-life, observational and retrospective study aims to evaluate the virological efficacy, toxicity and tolerability of Doravirine-based regimens in aged HIV-1 positive patients (> 50 years), focusing on metabolic patterns and inflammation markers.


Description:

HIV-infected individuals suffer from an accelerated aging due to the persistent and chronic activation of the immune system that leads to immune exhaustion and accelerated immunosenescence. The success of combination antiretroviral therapy, which also prolongs patients' survival, have relatively higher retention rates among HIV infected elderly patients, but only a small percentage are virally suppressed, largely due to elderly drugs interacts with ART and several comorbidities that reduces the life span of elderly people. In this context, Doravirine is the only NNRTI with a low propensity for resistance, excellent tolerability, a superior neuropsychiatric profile compared with EFV, a superior lipid profile compared with ritonavir-boosted darunavir and EFV, minimal risk for drug- drug interactions, and no food restrictions. In addition, doravirine has a large therapeutic index and robust efficacy in patients with high viral load. However, to date, data on doravirine in HIV aged patients are still lacking. This observational retrospective cohort in real world will aim to describe the effect of doravirine regimens, both as single drug and as fixed combination with lamivudine and tenofovir disoproxil fumarate, in aged HIV patients. - The primary endpoint will be the evaluation of virological efficacy defined as the proportion of patients with HIV RNA < 50 copies/mL at the end of the 48-week follow-up. - The secondary endpoints will be the following: - Change in CD4+, CD8 cell counts, CD4/ CD8 ratio from baseline to 48 weeks - Proportion of patients with any adverse events (AE), serious adverse events (SAE), also according to their severity. - Changes in total HDL and LDL-cholesterol, triglycerides, creatinine, eGFR, phosphate, AST, ALT, FIB-4, ALP, glucose, proteinuria from baseline to 48 weeks. - Changes of infiammatory biomarkers: D-Dimer, hsCRP and IL-6 during 48 weeks - Occurrence of genotypic mutations (genotypic test) in plasma samples from patients with virological failure Clinical data will be collected from medical records and laboratory analyses comprising CD4+ T cell count, plasma HIV-1 RNA, blood cells, and plasma chemistry profiles, including fasting lipids (total cholesterol, high-density lipoprotein cholesterol [HDL], low- density lipoprotein [LDL] cholesterol, triglycerides) will be recorded. The Time horizon for patient follow-up for outcome is at least 12 months (Baseline, 12, 24, 36, 48 weeks).


Recruitment information / eligibility

Status Recruiting
Enrollment 90
Est. completion date December 2022
Est. primary completion date December 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria: - HIV-1 infected patients - aged > 50 years old - naive patients receiving doravirine-based regimens both as single drug and as in fixed combination with lamivudine and tenofovir disoproxil fumarate - experienced patients with persistently undetectable plasma HIV viral load (HIV RNA < 50 copies/mL) for at least 6 months, who switched from any antiretroviral drug to doravirine-based regimens, both as single drug and as fixed combination with lamivudine and tenofovir disoproxil fumarate, because of toxicity, convenience or other reasons. - estimated creatinine clearance (CrCl) =50mL/min. Exclusion Criteria: - previous genotypic testing showing resistance mutations to doravirine - acute hepatitis, decompensated liver disease, liver cirrhosis - use of systemic immunosuppressive therapy

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Doravirine
Doravirine, both as single drug and as fixed combination with lamivudine and tenofovir disoproxil fumarate

Locations

Country Name City State
Italy Department of Public Health and Infectious Diseases Rome Italy/RM

Sponsors (1)

Lead Sponsor Collaborator
University of Roma La Sapienza

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Virological efficacy Assessing the virological efficacy (HIV RNA < 50 copies/mL) of the Doravirine regimen at the end of the follow-up. 48 weeks
Secondary Time to virological failure 48 weeks
Secondary Immunological changes Change in CD4+, CD8 cell counts, CD4/ CD8 ratio Baseline to 48 weeks
Secondary Safety profile Proportion of patients with any adverse events (AE), serious adverse events (SAE), also according to their severity. Baseline to 48 weeks
Secondary Lipid and metabolic profile Changes in total HDL and LDL-cholesterol, triglycerides, creatinine, eGFR, phosphate, AST, ALT, FIB-4, ALP, glucose, proteinuria Baseline to 48 weeks
Secondary Infiammatory biomarkers Evaluation of D-Dimer, hsCRP and IL-6 48 weeks
Secondary Resistance profile in patients with virological rebound Evaluation of of genotypic mutations occurrence (genotypic test) in plasma samples from patients with virological failure Baseline to 48 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT06162897 - Case Management Dyad N/A
Completed NCT03999411 - Smartphone Intervention for Smoking Cessation and Adherence to Anti- Retroviral Therapy (ART) Among People Living With Human Immunodeficiency Virus (HIV) Phase 4
Completed NCT02528773 - Efficacy of ART to Interrupt HIV Transmission Networks
Recruiting NCT05454839 - Preferences for Services in a Patient's First Six Months on Antiretroviral Therapy for HIV in South Africa
Recruiting NCT05322629 - Stepped Care to Optimize PrEP Effectiveness in Pregnant and Postpartum Women N/A
Completed NCT02579135 - Reducing HIV Risk Among Adolescents: Evaluating Project HEART N/A
Active, not recruiting NCT01790373 - Evaluating a Youth-Focused Economic Empowerment Approach to HIV Treatment Adherence N/A
Not yet recruiting NCT06044792 - The Influence of Primary HIV-1 Drug Resistance Mutations on Immune Reconstruction in PLWH
Completed NCT04039217 - Antiretroviral Therapy (ART) Persistence in Different Body Compartments in HIV Negative MSM Phase 4
Active, not recruiting NCT04519970 - Clinical Opportunities and Management to Exploit Biktarvy as Asynchronous Connection Key (COMEBACK) N/A
Completed NCT04124536 - Combination Partner HIV Testing Strategies for HIV-positive and HIV-negative Pregnant Women N/A
Recruiting NCT05599581 - Tu'Washindi RCT: Adolescent Girls in Kenya Taking Control of Their Health N/A
Active, not recruiting NCT04588883 - Strengthening Families Living With HIV in Kenya N/A
Completed NCT02758093 - Speed of Processing Training in Adults With HIV N/A
Completed NCT02500446 - Dolutegravir Impact on Residual Replication Phase 4
Completed NCT03805451 - Life Steps for PrEP for Youth N/A
Active, not recruiting NCT03902431 - Translating the ABCS Into HIV Care N/A
Completed NCT00729391 - Women-Focused HIV Prevention in the Western Cape Phase 2/Phase 3
Recruiting NCT05736588 - Elimisha HPV (Human Papillomavirus) N/A
Recruiting NCT03589040 - Darunavir and Rilpivirine Interactions With Etonogestrel Contraceptive Implant Phase 2